Literature DB >> 3765897

[Results of treatment with clozapine in schizophrenic adolescents].

G Siefen, H Remschmidt.   

Abstract

The indications for administering clozapine to 21 adolescent inpatients with schizophrenia were insufficient response to other neuroleptic agents, likelihood of psychotic symptoms becoming chronic and extensive extrapyramidal side-effects from other neuroleptic agents. Marked improvement in or complete disappearance of most of the remaining psychopathological symptoms was seen in 11 of the 21 subjects, with at least some improvement seen in an additional 6. Vegetative side-effects such as daytime weariness, dizziness, orthostatic hypotonia and hypersalivation were usually transient. Deviations from the normal range of values for the hematological and serum enzyme values assessed were of no clinical significance and occurred no more frequently than with other neuroleptic agents, and the values returned to normal when treatment was continued. On the whole, clozapine is a useful addition to the group of drugs available for treating adolescents with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3765897

Source DB:  PubMed          Journal:  Z Kinder Jugendpsychiatr        ISSN: 0301-6811


  8 in total

Review 1.  Typical neuroleptics in child and adolescent psychiatry.

Authors:  C Gillberg
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 2.  Types of psychiatric treatment. Drug treatment.

Authors:  M Prendergast
Journal:  Arch Dis Child       Date:  1992-12       Impact factor: 3.791

3.  Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Markus Mittendorf; Frank M Theisen; Karin Wolf-Ostermann; Phillip Grant; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-04-28       Impact factor: 4.785

Review 4.  Atypical neuroleptics in child and adolescent psychiatry.

Authors:  H Remschmidt; K Hennighausen; H W Clement; P Heiser; E Schulz
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

5.  Blood biogenic amines during clozapine treatment of early-onset schizophrenia.

Authors:  E Schulz; C Fleischhaker; H W Clement; H Remschmidt
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 6.  Tolerability profile of atypical antipsychotics in children and adolescents.

Authors:  K A Stigler; M N Potenza; C J McDougle
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 7.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 8.  Clozapine versus typical neuroleptic medication for schizophrenia.

Authors:  Adib Essali; Nahla Al-Haj Haasan; Chunbo Li; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.